From 7–9 May, DiCE virtually joined the AMMF European Cholangiocarcinoma Conference, hosted in London. Organised by AMMF, the UK-based charity dedicated to cholangiocarcinoma (CCA), the conference brought together international experts, researchers, patients, and advocates to share the latest developments in the field.

Over the past 23 years, AMMF has played a leading role in supporting people affected by CCA across the UK and Europe—providing information, advocating for earlier diagnosis and better treatments, and supporting research efforts.

The 2025 programme featured updates on advances in liquid biopsy, molecular profiling, targeted therapies, immunotherapy, liver transplantation, and surgery. It also offered a comprehensive overview of the current treatment landscape across the UK, Europe, and beyond.

A key focus was AMMF’s “Rethink Liver Cancer” campaign, which calls for wider recognition of CCA, alongside hepatocellular carcinoma (HCC), as a primary liver cancer. The event also placed strong emphasis on the experiences of patients, carers, families, and nurses, highlighting the need for person-centred approaches throughout the care pathway.

DiCE was pleased to connect with AMMF’s dedicated team and other stakeholders, returning with valuable insights to strengthen our continued advocacy for those affected by CCA.

Author:

Lili Anna Kuschnereit